Literature DB >> 33710334

Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival.

Ingrid Glimelius1,2, Karin E Smedby2,3, Alexandra Albertsson-Lindblad4, Michael J Crowther5,6, Sandra Eloranta2, Mats Jerkeman4, Caroline E Weibull2.   

Abstract

It is unknown how many mantle cell lymphoma (MCL) patients undergo consolidation with autologous hematopoietic cell transplantation (AHCT), and the reasons governing the decision, are also unknown. The prognostic impact of omitting AHCT is also understudied. We identified all MCL patients diagnosed from 2000 to 2014, aged 18 to 65 years, in the Swedish Lymphoma Register. Odds ratios (ORs) and 95% confidence intervals (CIs) from logistic regression models were used to compare the likelihood of AHCT within 18 months of diagnosis. All-cause mortality was compared between patients treated with/without AHCT using hazard ratios (HRs) and 95% CIs estimated from Cox regression models. Probabilities of being in each of the following states: alive without AHCT, alive with AHCT, dead before AHCT, and dead after AHCT, were estimated over time from an illness-death model. Among 369 patients, 148 (40%) were not treated with AHCT within 18 months. Compared with married patients, never married and divorced patients had lower likelihood of undergoing AHCT, as had patients with lower educational level, and comorbid patients. Receiving AHCT was associated with reduced all-cause mortality (HR = 0.58, 95% CI: 0.40-0.85). Transplantation-related mortality was low (2%). MCL patients not receiving an AHCT had an increased mortality rate, and furthermore, an undue concern about performing an AHCT in certain societal groups was seen. Improvements in supportive functions potentially increasing the likelihood of tolerating an AHCT and introduction of more tolerable treatments for these groups are needed.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2021        PMID: 33710334      PMCID: PMC7993102          DOI: 10.1182/bloodadvances.2020003645

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  29 in total

1.  Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.

Authors:  Christian H Geisler; Arne Kolstad; Anna Laurell; Mats Jerkeman; Riikka Räty; Niels S Andersen; Lone B Pedersen; Mikael Eriksson; Marie Nordström; Eva Kimby; Hans Bentzen; Outi Kuittinen; Grete F Lauritzsen; Herman Nilsson-Ehle; Elisabeth Ralfkiaer; Mats Ehinger; Christer Sundström; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Peter Brown; Erkki Elonen
Journal:  Br J Haematol       Date:  2012-05-29       Impact factor: 6.998

Review 2.  Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma.

Authors:  Constantine S Tam; Issa F Khouri
Journal:  Leuk Lymphoma       Date:  2009-08

3.  Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

Authors:  Steven Le Gouill; Catherine Thieblemont; Lucie Oberic; Anne Moreau; Krimo Bouabdallah; Caroline Dartigeas; Gandhi Damaj; Thomas Gastinne; Vincent Ribrag; Pierre Feugier; Olivier Casasnovas; Hacène Zerazhi; Corinne Haioun; Hervé Maisonneuve; Roch Houot; Fabrice Jardin; Eric Van Den Neste; Olivier Tournilhac; Katell Le Dû; Franck Morschhauser; Guillaume Cartron; Luc-Matthieu Fornecker; Danielle Canioni; Mary Callanan; Marie C Béné; Gilles Salles; Hervé Tilly; Thierry Lamy; Remy Gressin; Olivier Hermine
Journal:  N Engl J Med       Date:  2017-09-28       Impact factor: 91.245

Review 4.  Mantle Cell Lymphoma: Which Patients Should We Transplant?

Authors:  James N Gerson; Stefan K Barta
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

5.  Mantle cell lymphoma: therapeutic options in transplant-ineligible patients.

Authors:  Tadeusz Robak; Piotr Smolewski; Pawel Robak; Martin Dreyling
Journal:  Leuk Lymphoma       Date:  2019-04-25

Review 6.  Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment.

Authors:  Eva Hoster; Christiane Pott
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

7.  Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.

Authors:  Christian H Geisler; Arne Kolstad; Anna Laurell; Niels S Andersen; Lone B Pedersen; Mats Jerkeman; Mikael Eriksson; Marie Nordström; Eva Kimby; Anne Marie Boesen; Outi Kuittinen; Grete F Lauritzsen; Herman Nilsson-Ehle; Elisabeth Ralfkiaer; Måns Akerman; Mats Ehinger; Christer Sundström; Ruth Langholm; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Peter Brown; Erkki Elonen
Journal:  Blood       Date:  2008-07-14       Impact factor: 22.113

8.  A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.

Authors:  Eva Hoster; Martin Dreyling; Wolfram Klapper; Christian Gisselbrecht; Achiel van Hoof; Hanneke C Kluin-Nelemans; Michael Pfreundschuh; Marcel Reiser; Bernd Metzner; Hermann Einsele; Norma Peter; Wolfram Jung; Bernhard Wörmann; Wolf-Dieter Ludwig; Ulrich Dührsen; Hartmut Eimermacher; Hannes Wandt; Joerg Hasford; Wolfgang Hiddemann; Michael Unterhalt
Journal:  Blood       Date:  2007-10-25       Impact factor: 22.113

Review 9.  The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?

Authors:  Martin Dreyling; Simone Ferrero
Journal:  Haematologica       Date:  2016-02       Impact factor: 9.941

10.  Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP.

Authors:  Young-Woo Jeon; Joo-Hyun O; Kyung-Sin Park; Gi June Min; Sung-Soo Park; Jae-Ho Yoon; Ki-Seong Eom; Chang-Ki Min; Seok-Goo Cho
Journal:  Br J Haematol       Date:  2019-11-16       Impact factor: 6.998

View more
  1 in total

1.  Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007-2017.

Authors:  Alexandra Albertsson-Lindblad; Thorgerdur Palsdottir; Karin E Smedby; Caroline E Weibull; Ingrid Glimelius; Mats Jerkeman
Journal:  Haematologica       Date:  2022-03-01       Impact factor: 9.941

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.